BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, Marrone A, Macera M, Adinolfi LE, Giudice EM, Gentile I, Sagnelli E, Rossi F. CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. Dig Liver Dis 2016;48:1364-9. [PMID: 27476469 DOI: 10.1016/j.dld.2016.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F. Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One 2017;12:e0181890. [PMID: 28759568 DOI: 10.1371/journal.pone.0181890] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
2 Tahamtan A, Rezaiy S, Samadizadeh S, Moradi A, Tabarraei A, Javid N, Oladnabi M, Naeimi MH. Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects. J Mol Neurosci 2020;70:26-31. [DOI: 10.1007/s12031-019-01395-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Holloman BL, Nagarkatti M, Nagarkatti P. Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases. Int J Mol Sci 2021;22:7302. [PMID: 34298921 DOI: 10.3390/ijms22147302] [Reference Citation Analysis]
4 Howlett AC, Abood ME. CB1 and CB2 Receptor Pharmacology. Adv Pharmacol 2017;80:169-206. [PMID: 28826534 DOI: 10.1016/bs.apha.2017.03.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 20.2] [Reference Citation Analysis]
5 Argenziano M, Tortora C, Bellini G, Di Paola A, Punzo F, Rossi F. The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. Int J Mol Sci 2019;20:E5875. [PMID: 31771129 DOI: 10.3390/ijms20235875] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
6 Oláh A, Szekanecz Z, Bíró T. Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges. Front Immunol 2017;8:1487. [PMID: 29176975 DOI: 10.3389/fimmu.2017.01487] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]